RET
OverviewSuggest Edit
RET is a provider of transportation services. It offers metro, light rail, tram, buses, and ferry services.
| Type | Private | |
| Founded | 1878 | |
| HQ | Rotterdam, NL | Map |
| Website | werkenbijderet.nl |
Recent NewsAll News
- Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
- European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
- Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
- Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Latest Updates
| Employees (est.) (Apr 2022) | 1,724 | |
| Cybersecurity rating | A | More |
RET Financials and Metrics
Summary Metrics
Founding Date | 1878 |
RET Cybersecurity Score
RET Online and Social Media Presence
19.15k Twitter followers
RET has 19.15k Twitter Followers. The number of followers has increased 0.3% month over month and increased 1.6% quarter over quarter
RET's Trends
Twitter Engagement Stats for @retrotterdam
95.2k
Tweets
151
Following
19.2k
Followers
431
Tweets last 30 days
0.3
Avg. likes per Tweet
18.3%
Tweets with engagement
RET News and Updates
April 01, 2022
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
INDIANAPOLIS, April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo® (selpercatinib 40 mg & 80 mg capsules) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Retevmo (marketed as...
November 19, 2021
European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced no…
October 07, 2021
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
September 17, 2021
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged d…
RET Frequently Asked Questions
When was RET founded?
RET was founded in 1878.
How many employees does RET have?
RET has 1,809 employees.
Who are RET competitors?
Competitors of RET include Traxión, Autostrade Per L'Italia and CFI.
Where is RET headquarters?
RET headquarters is located at Laan op Zuid 2, Rotterdam.
Where are RET offices?
RET has an office in Rotterdam.
How many offices does RET have?
RET has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies